Compare
Hims & Hers Health, Inc. vs Teladoc Health, Inc. vs Starling Oncology, Inc. vs LifeMD, Inc.
| Latest fiscal year | Hims & Hers Health, Inc. HIMS | Teladoc Health, Inc. TDOC | Starling Oncology, Inc. STLN | LifeMD, Inc. LFMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.35B | $2.53B | $502.73M | $194.06M |
| Revenue growth (YoY) | +59.0% | -1.5% | +27.8% | +25.3% |
| Gross margin | 73.8% | n/a | n/a | 85.7% |
| Operating margin | 4.5% | -10.4% | -7.2% | -4.0% |
| Net margin | 5.5% | -7.9% | -12.1% | 7.4% |
| Net income | $128.37M | -$200.32M | -$60.61M | $14.35M |
| EPS (Diluted) | $0.51 | -$1.14 | -$0.54 | $0.25 |
| Operating cash flow | $300.01M | $294.36M | -$24.59M | $8.28M |
| Free cash flow | $57.41M | $285.46M | -$27.79M | $6.41M |
| Cash & equivalents | $228.62M | $781.08M | n/a | n/a |
| Total assets | $2.15B | $2.86B | $164.66M | $70.41M |
| Total liabilities | $1.61B | $1.47B | $180.38M | $47.25M |
| Shareholders' equity | $540.93M | $1.39B | -$15.72M | $23.16M |
| Return on year-end equity | 23.7% | -14.5% | n/a | 62.0% |
| Shares outstanding | n/a | 178.32M | 98.86M | 46.66M |
Revenue, most recent five fiscal years
| Fiscal year | Hims & Hers Health, Inc. | Teladoc Health, Inc. | Starling Oncology, Inc. | LifeMD, Inc. |
|---|---|---|---|---|
| Latest | $2.35B Ended 2025-12-31 | $2.53B Ended 2025-12-31 | $502.73M Ended 2025-12-31 | $194.06M Ended 2025-12-31 |
| 1 year earlier | $1.48B Ended 2024-12-31 | $2.57B Ended 2024-12-31 | $393.41M Ended 2024-12-31 | $154.82M Ended 2024-12-31 |
| 2 years earlier | $872.00M Ended 2023-12-31 | $2.60B Ended 2023-12-31 | $324.24M Ended 2023-12-31 | $152.55M Ended 2023-12-31 |
| 3 years earlier | $526.92M Ended 2022-12-31 | $2.41B Ended 2022-12-31 | $252.48M Ended 2022-12-31 | $119.03M Ended 2022-12-31 |
| 4 years earlier | $271.88M Ended 2021-12-31 | $2.03B Ended 2021-12-31 | $203.00M Ended 2021-12-31 | $92.88M Ended 2021-12-31 |